The QualityStocks Daily Monday, November 26th, 2018

Today's Top 3 StockMarketWatch

QualityStocks (MKRS) +29.03%

StockMarketWatch (ALACR) +27.27%

CannabisNewsWire (CHMJF) +26.82%

The QualityStocks Daily Stock List

PharmaCyte Biotech, Inc. (PMCB)

SmallCapNetwork, MyBestStockAlerts, OTCJournal, Penny Stock Laboratory, Stock Market Media Group, InvestorPlace, Goldman Small Cap Research, Damn Good Penny Picks, Penny Picks, Darth Trader, Wall Street Corner, Penny Stock General, PennyStockInformer, Cannabis Financial Network News, BUYINS.NET, Fast Money Alerts, Penny Stock Beats, Stock Shock and Awe, and The Stock Psycho reported previously on PharmaCyte Biotech, Inc. (PMCB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. centers on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This innovative and patented technology is being used as a platform upon which treatments for many types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. A clinical stage biotechnology enterprise, PharmaCyte Biotech is based in Silver Spring, Maryland. The Company lists on the OTCQB.

Additionally, PharmaCyte Biotech is working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other types of solid cancerous tumors. The Company’s treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form.

The capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. The live-cell encapsulation technology that PharmaCyte utilizes is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. It encapsulates living cells, not drugs. The Company is advancing its new treatment for pancreatic cancer into the clinic in the U.S., with study sites in Europe and Australia.

PharmaCyte is also developing treatments for cancer based upon chemical constituents of the Cannabis plant, called cannabinoids. The Company is studying ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.

This month, PharmaCyte Biotech announced that it selected Medpace, Inc. as the Contract Research Organization (CRO) to conduct PharmaCyte’s clinical trial in locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). Medpace is a scientifically driven, international, full-service clinical contract research organization (CRO). It provides Phase I-IV clinical development services to the biotechnology, pharmaceutical, as well as medical device industries.

Also, this month, PharmaCyte Biotech announced that it successfully completed a U.S. Food and Drug Administration (FDA) required formal report on the safety studies conducted by Bavarian Nordic using a pig model, which were undertaken before the initial clinical trial in humans utilizing cellulose-based capsules, which contain live genetically altered cells that activate the anticancer prodrug ifosfamide. The voluminous information contained in the formal report is another complicated Investigational New Drug Application (IND) component requested by the FDA to be included in the IND prior to the start of the clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).

PharmaCyte Biotech, Inc. (PMCB), closed Monday's trading session at $0.048, even for the day, on 2,216,821 volume with 82 trades. The average volume for the last 3 months is 1,543,279 and the stock's 52-week low/high is $0.034/$0.105.

chart

TechPrecision Corp. (TPCS)

BullRally, Stock Market News Alert, HotOTC, CoolPennyStocks, PennyStockVille, MadPennyStocks, Marketbeat, Energy and Capital, Wealth Daily, TopPennyStockMovers, Zacks, Stock Rich, FeedBlitz, SmallCapVoice, and StreetInsider reported on TechPrecision Corp. (TPCS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

TechPrecision Corp., by way of its wholly-owned subsidiaries, Wuxi Critical Mechanical Components Co., Ltd., and Ranor, Inc., is an industry leading manufacturer of precision, large-scale fabricated and machined metal components and tested systems. Its aim is to be an end-to-end worldwide service provider to its customers through furnishing customized and integrated turn-key solutions for completed products requiring custom fabrication and machining, assembly, inspection, and testing.

Established in 1956, TechPrecision has its corporate office in Westminster, Massachusetts. The Company’s shares trade on the OTC Markets Group’s OTCQB.

TechPrecision has the fabrication capacity to see a client’s large-scale components through from initial processing to final finishing and assembly. This does away with the need for outside servicing. Moreover, it helps ensure lower costs. TechPrecision’s products are used in the alternative energy, medical, nuclear, defense, and precision industrial, aerospace, and naval/maritime markets, among others.

The design of the Wuxi Critical Mechanical Components (CMC) subsidiary is to meet the increasing international demand for an experienced, knowledgeable machining and distribution center in Asia, providing large-scale component fabrication solutions for the area’s wind power and solar challenges. CMC uses one of the largest forges in the industry.

CMC’s capabilities include Forging; Fabrication; Machining; Inspection; Assembly & Finishing, and Quality Assurance. CMC serves the Solar/LED; Wind; Nuclear; Clean Technology, Medical; and General Industrial industries.

TechPrecision’s Ranor subsidiary specializes in large-scale, precision component fabrication for the Clean Technology, Energy, Medical, Aerospace, and Defense sectors. Ranor’s capabilities include Production Control; Engineering; Processing; Fabrication; Machining; Assembly & Finishing; Quality Assurance, and NDE & Inspection.

This month, TechPrecision reported financial results for Q2. Net Income for Q2 ended September 30, 2018 was $181,000 or $0.01 per share versus Net Income of $368,000 or $0.01 per share in the same quarter a year prior. Net Sales were $3.6 million, a $1.0 million decrease versus $4.6 million in the same quarter a year prior. The Q2 of fiscal year 2019 included $1.4 million of Revenue related to the adoption of ASC 606. Operating Income was $344,000 or 10 percent as a percentage of Net Sales.

Mr. Alexander Shen, Chief Executive Officer of TechPrecision, said, "We returned to targeted levels of project activity at the end of the second quarter, primarily with certain projects that have longer build cycles… Our Net Income was $181,000, a 10 percent improvement over first quarter Net Income. We expect to remain profitable over the next two quarters of fiscal year 2019 as we make progress to complete an increased number of projects."

TechPrecision Corp. (TPCS), closed Monday's trading session at $0.9425, up 2.45%, on 127,420 volume with 59 trades. The average volume for the last 3 months is 29,860 and the stock's 52-week low/high is $0.475/$0.949.

chart

Petrolia Energy Corp. (BBLS)

Insider Monitor, MarketWatch, Stockhouse, InvestorsHub, Infront Analytics, Capital Cube, Stockflare, OTC Markets, 4-Traders, Simply Wall St, GuruFocus, TradingView, and Market Exclusive reported previously on Petrolia Energy Corp. (BBLS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Petrolia Energy Corp.’s main concentration is employing inventive technology and the implementation of its own cutting-edge, proprietary technologies to improve the recoverability of existing oil fields. Its team of experts has a first-rate record of converting oil fields into compliant, producing, and profitable entities. Petrolia Energy’s primary goals are to locate undervalued assets, identify properties with resolvable environmental and mechanical issues, and lessen lift costs resulting in increased shareholder value. OTCQB-listed, Petrolia Energy is based in Houston, Texas.

The Company focuses on new oil wells in established areas of oil production. Petrolia has more than eight decades of operational and management experience throughout the energy industry. It announced in October 2016 that it purchased a 90 percent working interest (WI) via a purchase and sale agreement (PSA) and a share exchange agreement (SEA) with Jovian Petroleum Corp. and its subsidiaries, Jovian Resources, LLC and SUDS Properties, LLC, increasing its ownership to 100 percent WI for the Slick Unit Dutcher Sands (SUDS) field in Creek County, Oklahoma.

Petrolia Energy completed in 2017 the acquisition of a 60 percent net WI in the Twin Lakes San Andres Unit (TLSAU) lease, in Chaves County, New Mexico. This brings its total ownership of TLSAU to 100 percent. Overall, the TLSAU lease includes 4,864 gross and net acres; 2,292,903 barrels of 1P reserves; 44 existing vertical oil production wells, 12 that are now producing; 44 existing injection wells for water flood and/or CO2 injection for enhanced oil recovery (EOR); broad surface infrastructure, and a dedicated Caprock well to supply future water flood operations.

Petrolia Energy has signed the Slick Unit Exploration and Development Agreement with Boone Operating, Inc. to explore and develop the Misener and Simpson Formations at the Slick Unit Dutcher Sands Field (SUDS Field). Boone Operating is a private Exploration & Production company.

Petrolia Energy has also acquired a 25 percent Working Interest (WI) in the Luseland, Hearts Hill, and Cuthbert fields in southwest Saskatchewan and eastern Alberta. This acquisition consists of WIs in 64 sections (about 41,526 acres) with 240 oil and 12 natural gas wells producing on the properties.  Additionally, there are several idle wells with potential for reactivation and 34 sections of undeveloped land (about 21,760 acres).

Petrolia Energy has centered its acquisition efforts in core regions in Texas, New Mexico and Oklahoma. The Company is also pursuing its strategy to offer low-cost operational solutions in established plays, including the Minerva-Rockdale shallow oil play in Texas, the Dutcher Sands play in Oklahoma and its San Andres play in New Mexico.

Petrolia Energy Corp. (BBLS), closed Monday's trading session at $0.0901, even for the day, on 11,000 volume with 2 trades. The average volume for the last 3 months is 26,115 and the stock's 52-week low/high is $0.051/$0.469.

chart

The American Energy Group, Ltd. (AEGG)

Zacks, Stockhouse, 4-Traders, GuruFocus, The Street, MarketWatch, Wallet Investor, Marketbeat, Penny Stock Tweets, Stockwatch, Dividend Investor, Real Investment Advice, InvestorsHub, Research Gate, Market Screener, and Business Wire reported earlier on The American Energy Group, Ltd. (AEGG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The American Energy Group, Ltd. (AEGG) is an energy resource royalty company. It is a non-operating oil and gas organization. AEGG has an 18 percent gross overriding royalty interest on the producing Yasin Block 2468-7 in South-Central Pakistan, which consists of 539,172 acres. AEGG has its headquarters in Westport, Connecticut. The Company lists on the OTC Markets Group’s OTCQB.

AEGG’s strategy is to expand its portfolio of royalty and convertible WI’s in long-term petroleum leases. In addition, the Company’s strategy is to create shareholder value through investing in exploration and early development projects with high cash-flow potential. Its emphasis will be high-impact, South Asia energy development opportunities, which are characterized by many target structures and locations with a potential for substantial hydrocarbon reserves.

AEGG’s other core assets consist of royalties and convertible carried working interests (WI’s) in oil and gas leases. These include a 2.5 percent carried working interest (WI) in Zamzama North Block No. 2667-8 under exploration in South-Central, Sindh Province, Pakistan. Heritage Oil and Gas is the operator. This property comprises 557,951 square acres.

Furthermore, in the Zamzama North and Sanjawi Blocks, AEGG has the option to convert its 2.5 percent carried WI’s at any time, on a well by well basis to a 1.5 percent royalty, free of the costs of exploration and development of the leases. The convertible carried WI is "carried", which means free of exploration and development costs, as to the first three wells for Zamzama North, and the first two wells for Sanjawi.

Additionally, the Company has a 2.5 percent carried WI in Sanjawi Block No. 3068-2 under exploration in North-Central, Baluchistan Province, Pakistan. Heritage Oil and Gas is the operator. This property is 302,895 square acres. The other joint venture (JV) partners are Hycarbex-American Energy, Inc, Sprint Energy, and Trakker Energy.

Last month, AEGG announced that its subsidiary, Hycarbex-American Energy, Inc., the Operator of the Yasin 2768-7 exploration license in Pakistan, successfully revived the productivity of its Haseeb No. 1 Well. This was attained via workover activities required by intrusion of formation water into the wellbore in 2014. The surface well test on the Haseeb No. 1 Well was conducted between July 28, 2018 and August 5, 2018. The well produced gas at each of four varying choke sizes tested. Presently, Hycarbex is investigating the availability of gas processing services in the area. This is to render the gas suitable for pipeline sale and, alternatively, the availability of industrial gas customers who do not need processed gas for their operations. The Company anticipates that Hycarbex will commence marketing gas within the first calendar quarter of 2019.

The American Energy Group, Ltd. (AEGG), closed Monday's trading session at $0.09, even for the day, on 2,880 volume with 1 trade. The average volume for the last 3 months is 9,006 and the stock's 52-week low/high is $0.025/$0.14.

chart

Inspyr Therapeutics, Inc. (NSPX)

Zacks and BUYINS.NET reported earlier on Inspyr Therapeutics, Inc. (NSPX), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients with numerous different tumor types. Inspyr Therapeutics’ team has substantial pharmaceutical industry and scientific experience. The Company lists on the OTC Markets Group’s OTCQB.

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). Furthermore, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program focuses on the treatment of gastric cancer.

Inspyr has commenced a preclinical study in gastric cancer PDX tumor models, which express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.

In addition, the Company plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer.

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. The innovative platform technology has the potential to work across a range of drugs that precisely target different cancers.

In May 2017, Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced that they entered into an agreement to create an integrated company with a proprietary platform driving a pipeline of novel therapeutics. With this agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction. Lewis and Clark Pharmaceuticals is a privately-held biotechnology company.

In October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary compounds generated via the Company’s adenosine receptor modulator (ARM) technology platform. The preclinical study will assess adenosine receptor agonists for the management of atherosclerosis.

Furthermore, in October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics has fully-equipped, state-of-the-art organic and analytical chemistry laboratories in Charlottesville, Virginia. At these laboratories, a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.

Inspyr Therapeutics, Inc. (NSPX), closed Monday's trading session at $0.0054, up 12.50%, on 28,409,162 volume with 326 trades. The average volume for the last 3 months is 736,700 and the stock's 52-week low/high is $0.0028/$0.15.

chart

Mikros Systems Corp. (MKRS)

OTCEquity, PennyStocks24, AwesomeStocks, Wall Street Mover, PricelessPennyStocks, Promotion Stock Secrets, Marketbeat.com, Fast Money Alerts, Actual Gains, AddictivePennyStocks, Chatter Box Stocks, StockLockandLoad, PennyStockRumors.net, StockRockandRoll, StockBomb.com, ResearchOTC, and OTPicks reported on Mikros Systems Corp. (MKRS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mikros Systems Corp. is a provider of advanced maintenance and monitoring solutions for mission-critical systems. The Company is an advanced technology enterprise that designs and manufactures specialized electronic systems for the Department of Defense. Its chief business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. The Company is headquartered in Princeton, New Jersey, and has its Manufacturing and Depot Center in Largo, Florida.

Mikros produces advanced maintenance systems for the Navy. These include the ADEPT Maintenance Automation Workstation and the ADSSS Condition Based Maintenance system for the Littoral Combat Ship. ADEPT systems are in use daily for performance optimization of advanced radar systems.

The Company has developed, delivered, and installed military-grade equipment to Federal customers’ for more than 30 years. Its capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

Mikros Systems’ Lifecycle Support capability is focused on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to accomplish the highest levels of system readiness. The Company purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The main software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs.

The Diagnostic Profiler software is used globally by many multinational companies for optimized maintenance of varied product lines. Diagnostic Profiler is also used by the U.S. Air Force for depot test programs.

Prognostics Framework is used by the U.S. Army for many missile defense systems. These software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

In September 2017, Mikros Systems announced that it received the second production order awarded under its recent multi-year $35M contract with the Naval Surface Warfare Center in Crane, IN. This order covers new production deliveries of Mikros' Adaptive Diagnostic Electronic Portable Testset (ADEPT). It is valued at $2.4 million. The ADEPT units will be produced at the Mikros Manufacturing and Depot Center in Largo, FL.

Mikros has successfully completed the first ship and shore installation and testing of its ADEPT Distance Support Sensor Suite (ADSSS) on the Littoral Combat Ship USS INDEPENDENCE (LCS 2). As installed on LCS 2, ADSSS will utilize the Company’s proprietary model-based Prognostics Framework technology to monitor combat system elements to detect and predict on-ship system failures and apply predictive analytics to on-shore systems to detect broader maintenance trends and patterns across the fleet.

ADSSS Program Manager, Lori Ogles, said earlier in December, "Mikros has been a proud partner of the U.S. Navy for over fifteen years. We are honored to continue to support the readiness of U.S. Navy combat systems with our condition-based maintenance solution and we look forward to expanding the ADSSS technology to additional LCS and U.S. Naval platforms."

Mikros Systems Corp. (MKRS), closed Monday's trading session at $0.40, up 29.03%, on 5,650 volume with 7 trades. The average volume for the last 3 months is 14,160 and the stock's 52-week low/high is $0.259/$0.511.

chart

nFusz, Inc. (FUSZ)

MarketWatch and InvestorsHub reported on nFusz, Inc. (FUSZ), and we report on the Company today, here at the QualityStocks Daily Newsletter.

nFusz, Inc. (formerly bBooth) is a digital technology enterprise listed on the OTC Markets’ OTCQB. The Company’s proprietary next generation interactive video technology is the core of its new broadcast and cloud-based, Software-as-a-Service (SaaS) products. Its service is built around its proprietary 'Video-First' Notifi technology. This technology places interactive video front and center in all customer and prospect communications. nFusz has its corporate office in Hollywood, California.

nFusz products include notifiWEB. This product enables customers to create and display sales, product, or corporate videos with ‘clickable’ interactive links in the actual video on their ‘WordPress’ and other template-based websites, viewable on desktop and mobile devices.

In addition, nFusz has its notifiADS product. NotifiADS allows its customers to embed their interactive videos in online ads they can place almost anywhere online.

notifiCRM is the Company’s flagship product. notifiCRM is a cloud-based SaaS product. It is provided on a subscription basis, as a fully branded white labeled desktop, mobile, and web-based application (or embedded in customers’ existing applications via an API).

nFusz constructed an enterprise-class, fully scalable platform around its core technology for the creation and delivery of interactive videos as the centerpiece of a CRM and Lead Generation solution for any sales-based organization.

The Company also has its notifiLINKS product. With it, customers can take that same interactive video described in the aforementioned products, with all the interactive elements intact and distribute to them through Email; Text Messaging; Social Media; Electronic Invitations, and more.

nFusz provides subscription-based Customer Relationship Management (CRM), sales lead generation, and social engagement software on mobile and desktop platforms. These are for sales-based organizations, consumer brands, as well as artists looking for greater levels of engagement and higher conversion rates.
The Company’s software platform can accommodate any size campaign or sales organization. Moreover, it is enterprise-class scalable to meet the requirements of today's global organizations.

Last month,  nFusz announced that its notifiCRM product was approved by Financial Education Services (FES) for use by its 19,000 members and independent FES Agents. FES provides financial education and credit management training services to individuals all across the United States.

For a monthly subscription fee, as low as $9.99, individual FES members and Agents can take advantage of the power of the nFusz notifiCRM platform to distribute interactive video messages to educate and attract prospective new members. FES has helped members remove more than 1 million negative items from their credit reports.

nFusz Chief Executive Officer, Mr. Rory J. Cutaia, said, "We're very excited that FES has joined the ranks of companies now discovering the benefits of our notifiCRM platform, the only CRM product on the market utilizing interactive video, that helps sales-based organizations sell -- not just track the selling process -- but actually close sales."

nFusz, Inc. (FUSZ), closed Monday's trading session at $0.24, up 14.29%, on 325,172 volume with 93 trades. The average volume for the last 3 months is 456,107 and the stock's 52-week low/high is $0.071/$3.04.

chart

Astro Aerospace Ltd. (ASDN)

Stockwolf, Marketbeat, Stockopedia, Dividend Investor, Stockwatch, Barchart, Investors Hangout, YCharts, The Street, Stockhouse, 4-Traders, MarketWatch, Business Wire, Penny Stock Hub, OTC Markets, Simply Wall St, and Investors Hangout reported earlier on Astro Aerospace Ltd. (ASDN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Astro Aerospace Ltd. is the developer of the world’s most advanced autonomous, unmanned, and manned flying vehicles. It works to be at the forefront of this disruptive aerial industry. The OTCQB-listed Company explores ways to apply its technology to global challenges. These challenges include traffic congestion, pollution, as well as the overall stresses of daily life. Astro Aerospace is based in Lewisville, Texas.

Astro Aerospace’s in-house developed adaptive flight control algorithm keeps the ASTRO drone stable in most weather conditions, with minimal vibration. ASTRO Drones are a little bigger than a compact car. They can fit into most garages. ASTRO was expressly designed with wide cabin glass for optimal comfort and a 360 degree surround view. The vehicle has a complete carbon body and is equipped with 16 individual rotors.

The ASTRO features Fiber Optic Internal Communications; Touch Flight Control; Adaptive Flight Control Software; and Encrypted Communication Channels. Moreover, it features Field Oriented Motor Control; Fly-by-wire joystick; LTE (4G) network; and Glass Cockpit Avionics.

The ASTRO is suitable for operating in densely populated urban environments and it is an environmentally friendly solution. The design of its high-performance electric motor is to run quietly, fluidly, and totally emission-free. The Company’s drones do away with the need for gearboxes, water-cooling systems or aerodynamic steering flaps. The drones are outfitted with fiber optic technology.

Astro Aerospace acquired the assets to VTOL industry leader, Passenger Drone. Astro Aerospace’s Passenger Drone is a state-of-the-art aerial transport vehicle. It is scheduled to improve urban mobility and enable passengers to arrive at their destination quickly and safely.

Astro Aerospace announced this past September that it was granted a Special Flight Operations Certificate (SFOC). This is a permit for the operation of an unmanned air vehicle (UAV) system, for its passenger drone project, “Elroy”. Elroy is Astro’s two passenger eVTOL, short haul aerial vehicle that can travel up to 70km/hr for 25 minutes completely emission free.

This month, Astro Aerospace announced that the Astro Aerospace “Elroy” was featured in Electric VTOL News, one of the category leaders on the progress of electric and hybrid-electric powered Vertical Take-Off and Landing aircrafts. The article features the success of the “Elroy,” the Company’s PassengerDrone that was strategically acquired earlier in 2018, and that became the initial step of Astro's mission of “self-flying unmanned and manned vehicles becoming a mainstream mode of transportation.

The aforementioned Special Flights Operations Certificate (SFOC) that Astro received permitted the Company to conduct numerous unmanned flight tests just outside of Toronto at the Markham Airport. Astro has already started developing the Elroy 2.0. It should be introduced to the market in the next 6-9 months.

Astro Aerospace Ltd. (ASDN), closed Monday's trading session at $0.5693, up 3.51%, on 41,059 volume with 34 trades. The average volume for the last 3 months is 63,285 and the stock's 52-week low/high is $0.0209/$3.33.

chart

Humanigen, Inc. (HGEN)

Amigo Bulls, Corporate Information, Insider Financial, The Street, TradingView, OTC Markets, Investopedia, InvestorsHub, Barchart, Investors Hangout, Financial Times, Stock Invest, and Proactive Investors reported earlier on Humanigen, Inc. (HGEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. concentrates on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the Company’s portfolio include the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Derived from its Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Humanigen is based in Brisbane, California. The Company lists on the OTC Markets Group’s OTCQB.

Humanigen pursues innovative science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Lenzilumab has potential for the treatment of different rare diseases. These include hematologic cancers such as chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

Lenzilumab is a Humaneered® recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF). This is a critical cytokine that drives the growth of certain hematologic malignancies.

The other vital asset in the Company’s monoclonal antibody portfolio, ifabotuzumab, has been dosed in the first patient in an investigator-sponsored Phase 0/1 radio-labeled imaging trial in glioblastoma multiforme (GBM). Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created using Humanigen’s proprietary Humaneered® technology.

This month, Humanigen announced that final results from a preclinical study demonstrating that use of its proprietary, anti-GM-CSF monoclonal antibody, lenzilumab, in combination with CD19 targeted chimeric antigen receptor T (CART19) cell therapy prevents cytokine release syndrome (CRS), substantially lessens neurotoxicity (NT), and enhances CART19 proliferation and effector functions have been accepted as an oral presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH).

The oral presentation will include updated data not available in the abstract. The complete data set will be presented in the oral plenary session at the 2018 Annual Meeting of the American Society of Hematology, at 4:30 pm PT on Monday, December 3, 2018 at the Marriott Marquis San Diego Marina, San Diego Ballroom B.

Humanigen, Inc. (HGEN), closed Monday's trading session at $0.571495, up 3.91%, on 11,845 volume with 8 trades. The average volume for the last 3 months is 4,174 and the stock's 52-week low/high is $0.125/$0.80.

chart

Nemus Bioscience, Inc. (NMUS)

MarketWatch, InvestorsHub, OTC Markets, and Zacks reported on Nemus Bioscience, Inc. (NMUS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Nemus Bioscience, Inc. centers on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in worldwide markets. The Company’s strategy will explore the use of natural and synthetic compounds, alone or in combination. A highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development leads Nemus Bioscience. OTCQB-listed, the Company has its head office in Costa Mesa, California.

Using certain proprietary technology licensed from the University of Mississippi, Nemus Bioscience is working to develop novel ways to deliver cannabinoid-based drugs for specific indications. Its goal is optimizing the clinical effects of such drugs, while limiting the potential adverse events.

Cannabinoids are a class of chemically diverse compounds, which undergo extraction from the cannabis plant. These compounds express their physiological response through binding to specific cannabinoid receptors (CB1 and CB2) that are found throughout the body. Cannabinoids can specifically have impacts on the immune system, nervous system, as well as the body’s organs.

Nemus develops novel and proprietary classes of product candidates. The design of these are to improve therapeutic options by way of enhanced chemical engineering, which allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

Nemus Bioscience brings proprietary bioengineering to cannabinoid-based therapeutics to optimize therapeutic targeting. At present, the Company is the only partner of the University of Mississippi for the development and commercialization of these bioengineered cannabinoid-based drug candidates.

Nemus Bioscience is presently the only cannabinoid drug developer advancing a bioengineered multi-cannabinoid drug platform for the treatment of ocular diseases such as glaucoma. The Company is currently the only cannabinoid drug developer advancing a bioengineered multi-cannabinoid drug platform for the treatment and management of infectious diseases.

Additionally, Nemus is currently the only cannabinoid drug developer employing biosynthetic approaches for the manufacturing of Nemus Bioscience drug products.

Recently, Nemus Bioscience announced that it entered into agreements with Emerald Health Sciences, Inc., including a binding term sheet, Secured Promissory Note for a convertible loan and a Security Agreement. The Bridge Loan provides for aggregate gross proceeds to Nemus Bioscience of up to $900,000. It is secured by all of Nemus’ assets. Nemus received proceeds of $500,000 on December 28, 2017. The agreements provide for the funding of the remaining $400,000 on January 16, 2018.

Nemus Bioscience, Inc. (NMUS), closed Monday's trading session at $0.47, up 2.40%, on 302,839 volume with 146 trades. The average volume for the last 3 months is 528,947 and the stock's 52-week low/high is $0.05/$0.60.

chart

FogChain Corp. (FOGCF)

StockReads, 4-Traders, OTC Markets, InvestorsHub, MarketWatch, Barchart, Insider Financial, Stock Orange, Stockwatch, Bullish Guru, Penny Stock Hub, PressReader, Investors Hangout, Stockhouse, TradingView, Market Screener, and Wallet Investor reported earlier on FogChain Corp. (FOGCF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

FogChain Corp. is a totally integrated, end-to-end software development life cycle (SDLC) and quality assurance solutions provider. Its set of services and technology provides application development at scale with more speed, efficiency and at a lesser cost. FogChain's Build-Once Deploy-Everywhere software architecture provides developers with a set of tools and resources, which bridges devices, operating systems, and the ability to build and launch new applications in a unified environment. FogChain is headquartered in Vancouver, British Columbia and the Company lists on the OTC Markets’ OTCQB.

In essence, FogChain provides a next generation platform. This platform seamlessly integrates application development and deployment that leverages a high-performance Fog (or Edge) based computing network to drive scale and connects with the inventive and ground-up built RadJav Blockchain. The Company is introducing the next generation of decentralized compute to the world of software development and application lifecycle management.

Fog Computing uses decentralized and distributed computing resources and application services, which are closer to the Edge, or actual point of use. Fog Computing integrates with the most modern technologies. These include IoT (Internet of Things), Blockchain, 3D & Virtual Reality engines, and analytics tools. It can take advantage of underutilized resources, lessening costs.

FogChain has acquired RadJav, which provides developers with speedy application development tools and resources for the creation of mobile and web apps, smart contracts, and dApps. These are to be utilized across all major operating systems and devices on a unified platform. FogChain has also acquired Quilmont - a growing and profitable software development solutions provider specializing in automated testing, Continuous Integration and Deployment (CI/CD), mobile and website development, and software quality assurance.

Last week, FogChain announced that it commercialized and launched its Automated Application Testing Platform, Test Case Manager (TCM), an enterprise grade software application testing solution. TCM is a patented automated testing product. It allows organizations to accomplish considerable cost savings and improved time to market through automating their test cases.

The container-based solution consists of a sleek, web UI and a unique Selenium/Appium architecture, which product development teams work to attain. The container approach is highly scalable. It can exist onsite or accessed in the Cloud.

FogChain Corp. (FOGCF), closed Monday's trading session at $0.1116, up 1.45%, on 5,510 volume with 3 trades. The average volume for the last 3 months is 50,515 and the stock's 52-week low/high is $0.1019/$0.3639.

chart

Orgenesis, Inc. (ORGS)

IRGnews Alert, SmallCapNetwork, OTCPicks, Stock News Now, Greenbackers, Streetwise Reports, and pastwellness.com reported earlier on Orgenesis, Inc. (ORGS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Orgenesis, Inc. is a fully-integrated cell therapy and contract development and manufacturing company. It has a novel therapeutic technology for the treatment of diabetes. The Company has expertise and unique experience in cell therapy development and manufacturing. OTCQB-listed, Orgenesis is based in Germantown, Maryland.

In addition, the Company has a fully-owned subsidiary contract manufacturing and development company - MaSTherCell S.A. (Belgian subsidiary). This subsidiary’s dedication is to cell therapy for advanced medicinal products. MaSTherCell (a full-service contract development and manufacturing organization (CDMO)) specializes in the delivery of optimized process industrialization capacities to cell therapy organizations

Furthermore, by way of its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).

Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company uses a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Through its Israeli subsidiary, Orgenesis continues to advance its innovative cell-based therapy, the Autologous Insulin Producing (AIP) cells, into clinical development. AIP cells use the technology of 'cellular transdifferentiation' to transform an autologous adult liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell.

Orgenesis has demonstrated promising results in in-vitro and in-vivo studies using human liver tissues. It designed an efficient and clear work-plan to start clinical testing soon, allowing it to launch Phase I clinical trials following Food and Drug Administration (FDA) guidelines followed by the launch of Phase II clinical trials within a year.

In 2016, Orgenesis entered into a number of strategic partnerships and joint venture (JV) agreements. It entered into a JV Agreement with CureCell; it is collaborating in the contract development and manufacturing of cell therapy products in Korea.

Orgenesis Ltd, its Israeli subsidiary, entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL and CureCell in 2016. KORIL will provide funding for a joint research and development project for the use of AIP cells for the treatment of diabetes.

Orgenesis also entered into a JV agreement with Atvio Biotech Ltd., an Israeli company. This agreement is to collaborate in the contract development and manufacturing of cell and virus therapy products in the field of regenerative medicine.

Orgenesis, Inc. (ORGS), closed Monday's trading session at $5.87, up 6.15%, on 24,048 volume with 67 trades. The average volume for the last 3 months is 86,477 and the stock's 52-week low/high is $4.00/$16.79.

chart

Magellan Gold Corp. (MAGE)

Penny Stock Pick Report, Super Hot Penny Stocks, Super Nova Stock Picks, Penny Stock Pick Alert, RisingPennyStocks, Pumps and Dumps, SixFigureStockPicks, Greenbackers, PennyPickAlerts, PennyStockMoneyTrain, FOX Penny Stocks, Joe Penny Stocks, Liquid Tycoon, WePickPennyStocks, and Winning Penny Stock Picks reported on Magellan Gold Corp. (MAGE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Magellan Gold Corp.’s main business is the acquisition and exploration of mineral resources. The Company involves in the acquisition and exploration of precious metals mineral properties. Its updated strategic objective is building a mid-tier precious metals exploration and mining company. Magellan Gold is based in Vacaville, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Magellan Gold’s Silver District" project comprises 94 unpatented lode mining claims, 6 patented lode claims, an Arizona mining lease of 335 acres, and 23 unpatented mill site claims, totaling over 2,000 acres. Magellan holds its properties by way of its 85 percent owned subsidiary Gulf & Western Industries, Inc.

The Company’s district-scale property position covers the core of the historic Silver District in La Paz County, roughly 50 miles north of Yuma. At the Silver District Project in southwest Arizona, Magellan’s aim is to expand its resource base containing an historic resource of 16 million ounces of silver. Additionally, it plans to acquire more advanced-stage properties, which have tangible promise for development.

Magellan Gold has the right to earn an undivided 50 percent interest in the Niñobamba Silver/Gold Project in central Peru. To earn its 50 percent interest, it must spend $2.0 million in exploration over three years. The Niñobamba project encompasses 9,027 acres and demonstrates potential for a large, bulk tonnage, silver-gold deposit.

Regarding the Niñobamba Project, strategic additions to the land package have created a large, contiguous property consisting of 3100 hectares and another 553-hectare concession pending title confirmation. Magellan Gold will be spending US$2 million at the Niñobamba project to earn its 50 percent interest.

Magellan Gold announced in March of this year that it entered into a Memorandum of Understanding (MOU) with Rose Petroleum plc to purchase an operating floatation plant that also includes a precious metals leach circuit and associated assets, licenses and agreements (together, the SDA Mill), located in the State of Nayarit, Mexico, for a total consideration of US$1.5 million.

The basis of the mill's normal operation is on sales of floatation concentrates to smelters, and payment for precious metals content. The mill presently engages in toll milling for third party ore producers. Rose Petroleum is a multi-asset natural resource enterprise.

Effective for the month of November 2017, operations of the SDA Mill have re-started under an interim milling agreement between Magellan Gold and Rose and its Mexican operating subsidiary. At present, the processing plant is treating third-party ore on a toll basis at the rate of 100 tons per day.

Magellan Gold has funded costs of the interim operations under an approved budget. It will be entitled to proceeds from it. Until November 2017, milling activity was on hold pending the completion of the purchase transaction.

Magellan Gold Corp. (MAGE), closed Monday's trading session at $0.0221, up 0.45%, on 317,039 volume with 12 trades. The average volume for the last 3 months is 214,731 and the stock's 52-week low/high is $0.012/$0.0594.

chart

Rise Gold Corp. (RYES)

StockChase, MarketWatch, Marketwired, Stockhouse, 4-Traders, OTC Markets, and Streetwise Reports reported on Rise Gold Corp. (RYES), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rise Gold Corp. is an exploration-stage mining company listed on the OTC Markets Group’s OTCQB. The Company’s main asset is the historic past producing Idaho-Maryland Gold Mine located in the State of California. The Idaho-Maryland Mine was a significant past producer, yielding 2.4M oz of gold. Rise Gold has its head office in Vancouver, British Columbia.

There are manifold exploration targets today on the Idaho-Maryland Gold Mine property that is fully owned by Rise Gold. This includes surface and mineral rights. The Company owns all the mineral rights and there are no royalties on this private land. This Mine is near Grass Valley, California.

The Idaho-Maryland Gold Mine produced a total of 2,414,000 oz gold with an average mill head grade of 0.50oz/ton (approximately 17g/t). The Mine was producing up to 129,000 oz gold annually before being forced to shut down by the U.S. government in 1942. During WW II the U.S. War effort wanted to shut down precious metals excavation and shift the national mining workforce from gold to copper production.

This past September, Rise Gold announced that it negotiated an extension of the remaining payment due for the purchase of the 82-acre parcel of M-1 Industrial land neighboring the historic New Brunswick mine shaft in Nevada County, California. The extension of the payment terms will allow Rise Gold to center its financial resources on the exploration drill program at the Idaho-Maryland Gold Project.

The Mill Site property is directly adjacent to the Brunswick Mine shaft. This is where Rise Gold currently owns 37 acres of surface land. The Company’s belief is that the land purchase is a valuable addition to the Idaho-Maryland Gold Project.

In October, Rise Gold announced that exploration core drilling from surface began at the Idaho-Maryland Gold Project in Nevada County, California. The initial exploration drill hole was collared and cased to bedrock. Moreover, the rock core is now being logged.

The initial drill hole will drill through the Brunswick "Porphyrite" Block. It ends in the surrounding serpentinite that hosts the Idaho mineralization. The expectation is that the first hole will pierce several Brunswick style gold-quartz veins and stock-work zones.

Rise Gold Corp. (RYES), closed Monday's trading session at $0.0504, down 9.19%, on 44,200 volume with 9 trades. The average volume for the last 3 months is 79,453 and the stock's 52-week low/high is $0.0351/$0.165.

chart

The QualityStocks Company Corner

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CHMJF).

Chemistree Technology (CSE:CHM) (OTCQB:CHMJF) was highlighted today by Cannabis Penny Stocks.

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF) an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements’ expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company “maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S.”

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree’s working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed the day's trading session at $0.34, up 0.34%, on 18,674 volume with 9 trades. The average volume for the last 3 months is 2,009 and the stock's 52-week low/high is $0.268/$0.7158.

Recent News

chart

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (OTC: REFG) is a payment processing solution provider serving the state-sanctioned medical marijuana industry. Through Green or Take.Green, the company’s proprietary payment system, REFG tracks both sales and tax collection. This means that marijuana transactions are carried out above board and transparently. For the government, having such a system in place ensures efficient tax collection in an industry that has been dogged by tax evasion and underground deals.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.02165, up 25.87%, on 123,964 volume with 28 trades. The average volume for the last 3 months is 470,173 and the stock's 52-week low/high is $0.0165/$0.092.

Recent News

chart

RYU Apparel, Inc. (TSX.V: RYU) (OTC: RYPPF) (FRA: RYA)

The QualityStocks Daily Newsletter would like to spotlight RYU Apparel, Inc. (RYPPF).

RYU Apparel Inc. (TSXV: RYU, OTCQB: RYPPF) ("RYU" or the "Company"), creator of urban athletic apparel, is pleased to report its financial results for the three and nine months ended September 30, 2018. Also today, it was announced that RYU Apparel has officially opened the doors of its flagship store in Williamsburg, New York, as it continues its expansion into the United States.

Engineered for the fitness, performance and lifestyle of the athletically-minded, RYU Apparel, Inc. (DBA RYU \ Respect Your Universe) (TSX-V: RYU) (OTC: RYPPF) (FRA: RYA) develops, markets and distributes apparel, bags and accessories for active people living their lives with integrity. Headquartered in Vancouver, Canada, with with four stores located in Greater Vancouver Area, British Columbia and one in Toronto, RYU opened its first U.S.-based store at the iconic Abbot Kinney Boulevard in Venice California, on August 2, 2018. Additional retail locations are slated to open soon in Etokicoke, Ontario, Canada; Brooklyn, New York; and Newport Beach, California, with plans to establish nearly two dozen more store locations by the end of 2022.

Respect Your Universe’s award-winning brand celebrates, encourages and respects an individual’s choices and journey in life, promoting a fitness lifestyle culture. Innovatively designed without compromise and tailored for fit, comfort and durability, RYU exists to facilitate human performance. RYU’s urban athletic apparel and accessories product line has been featured by some of the most influential fitness and outdoor lifestyle publications and social media connectors.

The company recently was honored in Madrid, Spain, as a 2018 Finalist in the World Retail Awards in the categories of “Retail Start Up of the Year” and “Social Media Campaign of the Year,” (#RYUOneMoreRep). RYU is one of only two Canadian companies that qualified as finalists among many global retailers across all categories of the World Retail Awards annual event. The World Retail Awards have been recognizing the very best retailers and retail initiatives across a range of categories since 2007.

Marcello Leone, CEO of RYU, said the company’s inclusion in the prestigious lineup of finalists was gratifying, stating, “Being chosen by the World Retail Awards is a fantastic accolade. We are proud to be among a group of global peers that are considered to become the next generation of iconic brands. #RYUOneMoreRep Media Campaign is also another confirmation of the social aspect that permeates our brand and the impact we are having in our community.”

In addition to its retail locations, RYU generates sales through its e-commerce platform and has developed strategic relationships with companies such as Global-E, Netamorphosis, Fancy and the NHL Vancouver Canucks to expand its reach. RYU is also building connections with influential leaders and social media influencers who represent the company’s values of aliveness, bold expression, curiosity, discipline and respect. Under RYU’s Connector Program, each leader actively engages in community charities, volunteer efforts and participates in charity programs. Among the famous personalities and community leaders connecting with the RYU brand are:

  • Alexandra Ianculescu, a Canadian National Team Olympic Speed Skater
  • Ben Carr, professional trainer
  • Tori Katongo, personal trainer, singer, actor, dancer
  • Simon “Thor” Damborg, head coach at Raincity Athletics
  • Cassie Hawrysh, a Canadian National Team Skeleton Racer
  • Dai Manuel, lifestyle mentor and author of “The WholeLife Manifesto”

Company CEO Leon is the founder of Naturo Group Investment Inc., a company that sells nutritional beverages, and also is the former VP of operations and president of LEONE, an independent high fashion specialty store in Vancouver, Canada. Chief Financial Officer Pedro Villa is a certified CPA who has held several senior positions in various North American companies. Brett Pawson, senior VP of retail and operations, has more than 15 years of experience in sales and operations in the wellness, consumer goods and retail sectors.

RYU’s strategic focus is on becoming a global leader as a fitness and training apparel and accessories brand for athletes in multiple disciplines. RYU’s goal is to facilitate human performance by honoring and celebrating the extraordinary oneness of humanity by respecting each other’s differences – Respect Your Universe.

RYU Apparel, Inc. (RYPPF), closed the day's trading session at $0.112, up 15.46%, on 127,808 volume with 7 trades. The average volume for the last 3 months is 124,893 and the stock's 52-week low/high is $0.051/$0.255.

Recent News

chart

Sunniva, Inc. (CSE: SNN) (OTC: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Vertically integrated cannabis company Sunniva (CSE: SNN) (OTCQX: SNNVF) recently announced that it will be releasing financial results for the third quarter of 2018 after market close on Wednesday, November 28, 2018. To view the full press release, visit: http://nnw.fm/M6yAB. Also today, CannabisNewsWire released a report highlighting the company which examines the recent news that Canada legalized recreational cannabis on October 17 and the ongoing shortages aren’t the only thing that is having Canadians concerned. Many have expressed their displeasure regarding the amount of plastic packaging that comes with each gram of marijuana that they buy.

Sunniva, Inc. (CSE: SNN) (OTC: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $3.42, up 3.64%, on 56,014 volume with 97 trades. The average volume for the last 3 months is 101,282 and the stock's 52-week low/high is $3.105/$16.00.

Recent News

chart

Cyberfort Software, Inc. (CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

Cyberfort Software, Inc. (OTC: CYBF) recently issued an update on near-term corporate objectives (http://nnw.fm/9jldD). One of them is the negotiation of a purchase agreement to acquire Just Content Software, a multi-platform solution for content filtering and ad blocking. The acquisition will assist Cyberfort in the development of new solutions aimed at addressing some of the most common contemporary cybersecurity threats.

Cyberfort Software, Inc. (CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.36, up 2.86%, on 26,380 volume with 20 trades. The average volume for the last 3 months is 22,597 and the stock's 52-week low/high is $0.051/$69.00.

Recent News

chart

The Flowr Corporation (TSX.V: FLWR)

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation (FLWR).

The Flowr Corporation (TSX.V: FLWR), a vertically integrated Canadian cannabis company, this morning announced that it will release its financial results for the third quarter and nine months ended September 30, 2018, on Wednesday, November 28, 2018. Per the news release, this report will mark the company’s first release of financial results since the completion of its going-public transaction on September 21, 2018. Notably, Flowr’s results for these periods do not include any sales of cannabis products, as the company received its sales and production license in August 2018.

The Flowr Corporation (TSX.V: FLWR), a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

The Flowr Corporation (TSX.V: FLWR), closed the day's trading session at $3.41, up 0.29%, on 16,080 volume with 39 trades. The average volume for the last 3 months is 116,414 and the stock's 52-week low/high is $3.11/$8.00.

Recent News

chart

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

Through the exploration of its Irgon Lithium Mine Project, QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) is uncovering Manitoba’s full lithium production potential. Onsite work has delivered outstanding results, stimulating additional investment in exploration that is expected to lead toward production at the lithium mine on the property.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.187, off by 2.09%, on 33,300 volume with 15 trades. The average volume for the last 3 months is 100,232 and the stock's 52-week low/high is $0.1679/$1.46.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces its deepest discount for all online orders, as well as the biggest wholesale account discount. To view the Company’s broad range of cannabinoid products, visit https://EarthScienceTech.com. From now until midnight, all online orders are 50% off using promo code CYBERMONDAY at checkout.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.99, up 1.02%, on 21,239 volume with 40 trades. The average volume for the last 3 months is 118,426 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com, Inc. (OTCQB: CIIX), developer of a proprietary financial news media and content platform providing information to the global Chinese-speaking community, this morning announced that it will be a presenting company at the 11th Annual LD Micro Main Event to be held at the Luxe Sunset Blvd Hotel in Los Angeles on December 4-6, 2018. To view the full press release, visit: http://nnw.fm/zFR0x.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.57, off by 2.56%, on 79,600 volume with 50 trades. The average volume for the last 3 months is 551,977 and the stock's 52-week low/high is $0.365/$1.58.

Recent News

chart

American Premium Water Corp. (HIPH)

The QualityStocks Daily Newsletter would like to spotlight American Premium Water Corp. (HIPH).

American Premium Water Corporation (HIPH) announces that itsLALPINA CBD beverage will be sold with Fit Food Fresh (https://www.fitfoodfresh.com) in southern Florida along with its fresh prepared food plans. Fit Food Fresh, which is the highest rated food delivery program in South Florida, services customers Palm Beach, Dade, Browardand Martin counties, which,according the latest census figures, comprises 6,318,747 residents, the largest population concentration in Florida.

American Premium Water Corp. (HIPH), headquartered in Playa Vista, California, is a diversified holding company, manufacturer, distributor and marketer of branded consumer products. HIPH, the acronym for “Hi-Power of Hydro,” maintains a portfolio of subsidiaries catering to the health-conscious consumer and luxury fashion brand connoisseur. The company’s two main pillars focus on the development of health and beauty biotech, dedicated to unlocking the power of hydrogen and nanotechnologies. Paired with cannabidiol or “CBD” in a unique beverage, the technology is proving to be a significant health and wellness option for astute consumers.

Among the company’s holdings are:

  • LALPINA Hydro beverages mix hydrogen with nanotechnology into consumer beverages that combine the best of health, nutrition and fitness to deliver short and long-term therapeutic health benefits. LALPINA Hydro utilizes atomic molecular hydrogen, or diatomic hydrogen, which converts antioxidants in the body to H2O to further enhance hydration, which helps increase endurance, reduce lactic acid and melt away fatigue. Over 500 peer-reviewed articles demonstrate hydrogen to have therapeutic potential in essentially every organ of the human body and in 150 different human disease models.
  • LALPINA Hydro CBD is a technically superior CBD-infused beverage. Using hydro and nanotechnology, LALPINA Hydro CBD encapsulates water molecules with cannabidiol molecules, making them infinitely more bioavailable and accelerating delivery to the body’s cells and tissues. Each bottle of LALPINA Hydro CBD contains 3 million nanograms of CBD free from the psychoactive compound THC (tetrahydrocannabinol). HIPH is the first to introduce a hydro-nano CBD-infused beverage on the market, which is a more effective delivery mechanism for administering CBD into the blood stream than traditional beverages or oils, with up to a 90 percent higher absorption rates.

The company recently signed a distribution agreement for its subsidiary, LALPINA Hydro CBD, to sell its beverages to two SinglePoint, Inc. (OTCQB: SING) e-commerce channels: SingleSeed.com and DIGSHydro.com. SING is a technology and investment company with a portfolio that includes mobile payments, blockchain solutions and ancillary cannabis services. HIPH will drop ship its product to the customers.

HIPH CEO Ryan Fishoff said the e-commerce arrangements “could bring in excess of a million of revenue over the life of the agreement.” The agreement serves as a pillar of the company’s e-commerce distribution strategy, driving awareness and impressions for the LALPINA brand.

In addition, HIPH seeks to market emerging fashion brands and leverage its relationship with classic retail partners while incorporating disruptive blockchain technologies to expand its retail footprint with the following:

  • Gents, a producer of luxury hats and other fine accessories and apparel, was acquired in September 2017. Gents is distributed across many luxury retail outlets including Saks Fifth Avenue, Bloomingdales, Nordstrom, and other high-end channels. The company added the Worthy streetwear brand to its portfolio in June 2018.
  • HIPH also acquired the license to operate the FashionCoinX exchange, a blockchain exchange focused on creating utility tokens for the fashion industry, and created THRD Coin, a multi-branded utility rewards token that is also the first token to be traded on the exchange. The company is leveraging its retail footprint and expertise in the fashion and apparel space with the burgeoning blockchain sector.

American Premium Water Corp. (HIPH), closed the day's trading session at $0.0398, up 4.74%, on 9,796,231 volume with 329 trades. The average volume for the last 3 months is 18,468,223 and the stock's 52-week low/high is $0.0035/$0.1319.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

www.Investorideas.com, a global news source covering marijuana and hemp stocks and its cannabis podcast site www.potcasts.ca, report from Podcast Row in Las Vegas at this year’s biggest MJBizCon show to date. Today’s special edition features an interview with the management of SinglePoint, Inc. (OTC: SING), Mr. Gregory P. Lambrecht Founder, Chairman, CEO and Mr. William Ralston, President and Director discuss the growth of the MJBizCon conference, the industry and their company.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.01982, off by 0.90%, on 2,204,473 volume with 113 trades. The average volume for the last 3 months is 4,553,724 and the stock's 52-week low/high is $0.0178/$0.133.

Recent News

chart

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing  a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, including metastatic cancers, human immunodeficiency virus (HIV) and graft-versus-host disease (GvHD) is pleased to announce that on November 23, 2018, it received FDA approval of its IND submission and is allowed to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast cancer (TNBC) patients. Also today, the company was highlighted in the Venture Breakfast Bits, by 24/7 Market News. Full press release.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.618, off by 0.32%, on 534,087 volume with 129 trades. The average volume for the last 3 months is 222,001 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has submitted a Health Canada research application, and appointed Dr. Ed Ergenzinger to its executive team. The Company has submitted its research application under Health Canada's Cannabis Tracking and Licensing System for the operation of a Kelowna-based R&D laboratory within Lexaria's new head office under construction, to work with cannabinoids.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.19, off by 5.56%, on 133,136 volume with 163 trades. The average volume for the last 3 months is 236,106 and the stock's 52-week low/high is $0.741/$2.54.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a global producer of farm grown, high quality organic cannabis, has secured a strong entry point with provincial cannabis and liquor boards across Canada through a recently announced supply partnership with Velvet Management Inc. The company’s commitment to best-in-class distribution for its premium, certified-organic cannabis makes relationships with and sales through provincial cannabis and liquor boards critical to TGOD’s success.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.3491, off by 7.15%, on 446,326 volume with 815 trades. The average volume for the last 3 months is 1,563,384 and the stock's 52-week low/high is $1.87/$7.894.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.